Global Asperger Syndrome Market Size, Share, Forecast Report, 2020-2027

The Asperger syndrome is a type of developmental disorders known as Autistic Spectrum Disorder (ASD). These disorders initiate in childhood and stay with individuals until their adult life. Children with the Asperger syndrome function better than those with autism, and they have normal intelligence and language development. Although they may develop problems while communicating as they get older. Some of the common symptoms of the Asperger syndrome include repetitive behaviors, unusual preoccupations or rituals, limited range of interests, problems with social skills, communication difficulties, and coordination problems.

According to the statistics suggested by the World Health Organization (WHO), around 1 in 160 children are dealing with Autism Spectrum Disorder (ASD). Evidence-based psychosocial interventions, such as parent skills training programs and behavioral treatments can reduce difficulties in communication and social behavior in ASD patients.

It is noted that increasing technological advancements, government-sponsored awareness programs for autism, and the increasing prevalence of autism and related complications are the key factors driving the Asperger syndrome market.

Various other factors such as the growing awareness of autistic spectrum disorder, increasing patient pool, unmet medical needs, enhancing regulatory framework, increasing government assistance, and rising funding and reimbursement are continuously contributing to the growth of the global Asperger syndrome market.

Despite these drivers, there are some setbacks associated with the Asperger syndrome market. The side-effects associated with the drugs, strict FDA regulations, and poor healthcare system in low- and middle-income countries may hinder the growth of the market to a considerable extent.

It is estimated that the Asperger syndrome market is expected to grow at a CAGR 6.0% during the forecast period of 2017–2023.
Segmentation

The global Asperger syndrome market is segmented by diagnosis, treatment, and end-user.

By diagnosis, the market is classified as DSM-IV, differential diagnosis, childhood Asperger syndrome test, Gilliam Asperger's Disorder Scale (GADS), Krug Asperger's Disorder Index (KADI), and others. The differential diagnosis is further classified as schizophrenia spectrum, personality disorder, nonverbal learning disorder, social anxiety disorder, Tourette syndrome, obsessive-compulsive disorder, major depressive disorder, pragmatic semantic disorder, stereotypic movement disorder, bipolar disorder, and others.

By treatment, the market is classified as parent education and training, social skills training, speech-language therapy, Applied Behavioral Analysis (ABA), sensory integration/occupational therapy, and medication. The medication segment is further classified as antipsychotics, selective serotonin reuptake inhibitors, psychiatric agents, and others. Antipsychotics include risperidone, paliperidone, and aripiprazole. The selective serotonin reuptake inhibitors include fluvoxamine, fluoxetine, sertraline, paroxetine, citalopram, and escitalopram. The psychiatric agents include atomoxetine and guanfacine.

On the basis of end-user, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.
Key Players

Some of the key players in the global Asperger syndrome market are Eli Lilly and Company's, Shire, Jazz Pharmaceuticals, Pfizer, GlaxoSmithKline, Forest Laboratories, Inc., Johnson and Johnson, Bristol-Myers Squibb, Otsuka Pharmaceutical Company, Ltd., Johnson & Johnson Services, Inc., AstraZeneca, Allergan, Inc., and others.